JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
This invention relates to JAK1 selective inhibitors, particularly pyrrolo[2,3-d]pyrimidine and pyrrolo[2,3-b]pyridine derivatives, and their use in treating myelodysplastic syndromes (MDS).
Saved in:
Main Author | |
---|---|
Format | Patent |
Language | English |
Published |
01.12.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | This invention relates to JAK1 selective inhibitors, particularly pyrrolo[2,3-d]pyrimidine and pyrrolo[2,3-b]pyridine derivatives, and their use in treating myelodysplastic syndromes (MDS). |
---|---|
Bibliography: | Application Number: US202117556374 |